BioCentury
ARTICLE | Company News

Forge, Basilea to develop antibiotics against unexploited targets

May 2, 2019 11:09 PM UTC

Forge and Basilea Pharmaceutica International Ltd. partnered to discover, develop and commercialize antibiotics against two undisclosed metalloenzyme targets the partners say have been difficult to drug.

Basilea will pay an undisclosed upfront payment to access Forge's Blacksmith metalloenzyme chemistry platform. Forge Therapeutics Inc. (San Diego, Calif.) is eligible to receive up to $167 million in development and sales milestones per target, plus tiered royalties...